Board Institutes Inter Partes Review Of Horizon Drug Patent
ALEXANDRIA, Va. — The Patent Trial and Appeal Board on Sept. 28 agreed to review various claims of a patented method of using the drug glyceryl tri-(4-phenylbutryate) (HPN-100) to treat subjects...To view the full article, register now.
Already a subscriber? Click here to view full article